Therapeutic antibody discovery & development

YUMAB is a German biotech company founded in 2012, focused on accelerating biotherapeutic innovation by offering contract and partnered research for the development of therapeutic antibodies from target identification to optimised lead candidates. The company aims to bridge the gap between research innovation and therapeutic application, providing state-of-the-art recombinant antibody technologies to researchers across various sectors. YUMAB's advanced antibody platform supports all antibody drug modalities, delivering fully human and humanised therapeutic candidates, optimised for manufacturing and clinical development. The platform leverages diverse antibody libraries and broad immune repertoires from various animal species, enabling rapid identification of optimal drug candidates for even challenging targets. YUMAB’s proven in vitro discovery technologies allow the pre-design of functional and biophysical properties, with antibody candidates identified within weeks and developed into formats such as full-length IgG, Fab, scFv, and more. With a successful track record in over 400 projects and numerous clinical candidates, YUMAB's innovations have led to significant advancements, including the spin-off of CORAT Therapeutics to develop a COVID-19 antibody in just 11 months. The company continues to expand its expertise through collaborations in areas like AI-assisted discovery, tumour target discovery, and TCR-like antibodies. YUMAB is a trusted partner, offering customised services and flexible licensing options to accelerate the translation of research into drug development.

^{* Advertisement - in cooperation with YUMAB GmbH*}